CATCo Regulatory News (CAT)

15 Jun 2006 12:45

GoldmanSachs International15 June 2006 FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION Name of exempt principal trader Goldman Sachs InternationalCompany dealt in CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLCClass of relevant security to which the Ordinary Sharesdealings being disclosed relate (Note 1) Date of dealing 14 June 2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities purchased Highest price paid (Note 3) Lowest price paid (Note 3) 400 13.0933 GBP 13.0933 GBP Total number of securities sold Highest price received (Note 3) Lowest price received (Note 3) 61436 13.0831 GBP 13.0436 GBP (b) Derivatives transactions (other than options) Product name, Long/short (Note 4) Number of securities (Note 5) Price per unit (Note 3) e.g. CFDCFD Long 1623 13.0436 GBPCFD Long 8785 13.0436 GBPCFD Long 4772 13.0436 GBPCFD Long 1500 13.1408 GBPCFD Long 400 13.0933 GBP (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product name, Writing, selling, Number of securities to Exercise Type, e.g. Expiry Option money purchasing, which the option relates American,e.g. call varying etc. (Note 5) price European date paid/received peroption etc. unit (Note 3) (ii) Exercising Product name, e.g. call option Number of securities Exercise price per unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relatingto the voting rights of any relevant securities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form isreferenced. If none, this should be stated. Date of disclosure 15 June 2006 Contact name Peter Highton Telephone number +44-207-774-1935 Name of offeree/offeror with which connected AstrazenecaNature of connection (Note 6) Advisor Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange